Biotech Stocks
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
FiercePharma
4h ago
With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”
Discussion
Sign in to join the discussion. Comments loading…